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Abstract
The Pap smear is one of the modern success stories in the field of preventive medicine. Since its
introduction as a screening test, there has been a dramatic reduction in the incidence of cervical
cancer. However, the search for a better screening test continues. The new technologies, including
liquid-based cytology (LBC), Human Papilloma Virus (HPV) testing and automated or machine-
assisted screening have been introduced. However, there is continuous debate about whether
society's limited resources are better spent on reaching the underserved rather than on these
technologies. Another question is whether these technologies create yet another kind of disparity
in delivering preventive care. For example, despite the wide use of LBC (99% of tests submitted to
our laboratory are LBC), conventional Pap smears are still used to screen/follow up some women.
It is not clear why some providers continue to prefer conventional smear over LBC and what are
the barriers for adopting LBC in cervical cancer screening. We hypothesize the lower cost of
conventional compared to LBC Pap testing, patient's lower socio-economic indices, a patient's
medical history and provider's subspecialty/training all appear to play a role in the choice of using
conventional Pap testing rather than LBC. Unintentionally, this choice results in repeat testing,
delayed treatment and potentially higher costs than intended. The ultimate goal of this review
article is to understand and explore possible barriers and disparities to adopting new technology
in cancer screening.
Review
Worldwide, cervical cancer remains one of the leading
causes of cancer in women [1]. Pap testing is a simple, safe
and economic screening test. In the USA, thanks to screen-
ing programs which were initiated more than 50 years
ago, the incidence of invasive cervical cancer has dramati-
cally declined. In the last two decades, although there has
been a reduction of cervical cancer rates, the reduction
had been relatively plateaued during the time period of
1981 to 1997 [2]. Lately, new technologies, such as LBC,
Human Papilloma Virus (HPV) testing and automated or
machine assisted screening, have been introduced into
cervical cancer screening. For many reasons including
aggressive marketing, these technologies have replaced
the apparently less expensive conventional Pap smear.
According to the Washington G2 report, this change has
dramatically increased the national expenditure from
$1.25 billion to 2 billion (60% increase) [3]. There is a
continuous debate, however, on the use and potential
abuse of the utilization of these technologies, and on the
role of aggressive marketing rather than the ultimate evi-
dence based medicine, in implementing these technolo-
gies as screening tests and, lastly, on the role of cost as the
ultimate barrier to their adoption.
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Evidence of superiority of LBC over Conventional Pap 
smears
The accuracy of cervical cytology depends on the quality
of the specimen, the preparation of the slide material, and
the cytologic interpretation. Sampling technique is of
utmost importance [4,5]. Errors in sampling and prepara-
tion may be the major cause of false-negative or unsatis-
factory Pap smear results [6]. Limitations of the
conventional Pap smear are the need for rapid fixation,
clumping, and the overlapping of cells with variable thick-
nesses of the smear. Abnormal cells may be obscured by
blood, mucus, and other debris, which potentially leads
to an increase in false-negative and equivocal (i.e.,
ASCUS) results. Slide preparation techniques that use a
fluid medium (LBC) have been developed to produce thin
layer smears to overcome these limitations.
LBC has been shown to improve the detection rates of cer-
vical intraepithelial neoplasia, both high and low grades,
and both squamous and glandular lesions [7-11]. It has
also been noted that there are improvements in inter-
observer variability [12] and a substantial decrease in
inadequate or unsatisfactory smears when utilizing LBC
[9]. Some reports document a significant reduction in the
false negative rates and improved sensitivity with the use
of LBC [8,13,14]. Bernstein, et al, also reported improved
sample adequacy leading to improved diagnosis with the
use of LBC [15].
At face value, LBC is more expensive than conventional
preparations. However, the cost effectiveness may be con-
sidered in terms of fewer repeat smears and fewer false-
negative cases, most likely as a result of improved sam-
pling. The British National Health Service, through its
National Institute of Clinical Excellence, suggests that the
LBC technology is economically a better model for screen-
ing for cervical pathology. In their study, Doyle, et al. [16]
showed a greater than 30% improvement in productivity
even if only 73% of the workload was converted to LBC.
They also documented that this conversion was slow for
the first two years of operation, most probably because of
the period of adjustment to the new system. During this
period, a number of measures were put in place in order
to assure quality; such as double screening of all LBC
cases. The most consistent improvements shown with LBP
in the literature are in the detection of low-grade abnor-
malities. Williams, et al. [17] reported that the most sig-
nificant impact of LBC in their laboratory has been on the
rate of unsatisfactory smears which fell from 13.9% with
conventional smears, to 1.9% with LBC. The most com-
mon reason for unsatisfactory smears with conventional
Pap smears are due to air-drying artifact, and obscuring
inflammation. These problems are very rare or absent
with LBC, giving a much lower rate for unsatisfactory
smears. The success of LBC is clearly reflected in the clinics
remaining less busy with return/repeat business, although
handling a similar load of patients. In one study, prior to
LBC, almost 25% of referrals (544 women) were for
repeated unsatisfactory smears, but this problem has now
almost disappeared, with only 11 women (0.5%) referred
in 2003–2004 for this reason [17]. The absolute number
of smears reported as showing a glandular abnormality or
adenocarcinoma showed a decrease from 66 in 2001–
2002 to 45 in 2003–2004. Thus, accuracy is higher, as
similar numbers of lesions have been found with both
conventional smears and LBC, with fewer glandular
abnormality reports with LBC. This may suggest that there
has been a lower likelihood of overcalling reactive glandu-
lar lesions with LBC.
According to Williams et al, [17] the workload in their lab-
oratory has decreased since the use of LBC. The reasons for
this include a decrease in unsatisfactory smears and the
fact that LBC smears take less time to screen than conven-
tional smears. Their experience has been that the time
taken for a full primary screening has decreased by
approximately 40%. There is also an improvement in
turnaround times, and backlogs of cases for primary
screening have disappeared leading to an improved
morale in the laboratory.
Evidence of a lack of advantage of LBC over conventional 
Pap smears
Recently the superiority of LBC over conventional Pap
smears has been questioned. In a randomized clinical trial
from South Africa, Taylor, et al. [18] compared the diag-
nostic performance of LBC (3184 patients [56.4%]) vs.
the diagnostic performance of conventional Pap smears
(2463 patients [43.6%]). In contrast to previous findings,
they found that the accuracy of both modalities was
equivalent – the conventional smear slightly better than
LBC. Surprisingly, LBC provided more unsatisfactory sam-
ples in comparison to the conventional smears (2.2% vs.
0.8%). (In another publication, Davey, et al. [19] com-
piled data from 56 studies with a sample size of 1.29 mil-
lion tests. In their study, the classification of high grade
squamous intraepithelial lesion varied according to study
quality (p = 0.04) with conventional cytology classifying
more slides in this category than did LBC in high quality
studies (n = 3) only).
Current recommendations for the use of the conventional 
Pap smear
The current recommendations by different national
organizations regarding the use of conventional Pap
smears or the use of LBC are not entirely clear. In fact,
some organizations do not favor or discourage the use of
the conventional Pap.CytoJournal 2007, 4:16 http://www.cytojournal.com/content/4/1/16
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According to the recommendations by the U.S. Preventive
Services Task Force (USPSTF) [20], "the evidence is insuf-
ficient to recommend for or against the routine use of new
technologies to screen for cervical cancer". Although the
American Cancer Society has no preference for LBC over
conventional Pap tests, it is worth noting that it recom-
mends [21] biennial instead of annual screening if LBC is
used instead of conventional Pap smears. ACS suggests
that mild abnormalities, seen more frequent with LBC
than with conventional smears, lead to unnecessary repeat
testing and over-management. The American Society for
Colposcopy and Cervical Pathology (ASCCP) guidelines
[22] do not have a preference for conventional smears
over LBC.
On the other hand, the British National Health Service
recommends [23]the use of LBC as the primary means of
processing samples for cervical screening in England and
Wales. This is based on technical superiority rather than
the diagnostic performance of LBC. LBC improves slide
preparation, presents a more homogenous sample, and
makes the slides easier to read with subsequent increase in
productivity. The Danish Center for Evaluation and
Health Technology Assessment concludes that from a sci-
entific view either a conventional preparation or a LBC
can be chosen [24].
HPV testing and the HPV vaccine
The cost effectiveness of HPV testing is recognized for
patients with a diagnosis of ASCUS. There is also some
evidence of the effectiveness of HPV testing and cytology
evaluation as primary screening methodology for women
>30 years [25,26]. However, whether screening with the
combination of HPV testing and cytology for women
greater than 30 years will be accepted by women and phy-
sicians is unclear [27]. In spite of its effectiveness, the cost
of testing may prove to be a barrier for the wide use of
HPV testing. Currently, there is no data supporting or
refuting this possibility. HPV vaccine is now being consid-
ered for girls in the age group of 9 to 13 yrs [28]. It will
take some time for implementation of this vaccine. The
barriers encountered with vaccines are many and may not
be different than barriers encountered when other types of
vaccines were first introduced into the marketplace [28-
31].
Automated/Image assisted screening
Automated screening is successful for a wide screen for
cervical cancer screening strategies. It has also been shown
that automated/image assisted screening is cost-effective,
especially in high risk populations [32]. The literature also
shows that the use of automated screening reduces the
number of false-negative Pap smears [33]. Barriers for the
use of automated screening are not well defined, although
the initial investment/cost for purchase may be one such
factor.
A System-based approach for assessing possible barriers 
for adopting recent technologies
It is simplistic to assume that a single factor could explain
the preference of one screening method over another. In
evaluating barriers to preventive clinical care, Walch and
McPhee proposed an innovative model [34] to analyze
the different factors that influence the patient and physi-
cian choice of preventive measure/behavior such as the
Pap test. This model borrows from communication,
behavioral, health education and psychological theories
and simplifies the analysis of patient-physician interac-
tion.
This is an innovative empirical model which assumed that
the duty of obtaining the recommended preventive care
such as a Pap test is not only the responsibility of the
women, but a collective result of many interactive factors
including those that are related to the individual woman,
to the physician counseling the patient, to the healthcare
organization (usual place of care), and to the diagnostic
performance as well as the cost-effectiveness of the test
itself (Figure 1).
The immediate result of this interaction may be the per-
formance of a Pap test with subsequent detection and
treatment of intraepithelial lesions – an act which ulti-
mately leads to the reduction of the incidence of cervical
cancer. As suggested by Walsh and McPhee [34], the dif-
ferent factors that result in successful screening could be
conceptually viewed as a system or as "a cause and effect
– fishbone diagram" in which these factors interact to pro-
duce the ultimate outcome [34]. For instance, choosing
LBC over the conventional method for a Pap test may be
associated with decreased numbers of inadequate Pap
smears and a better yield for the diagnosis of dysplasia
leading to better cytology/histology correlation and
avoidance in the delay in the diagnosis of lesions, which
leads to better management.
Patient predisposing factors include age, race, education
and income. Physician predisposing factors include age,
years since graduation from medical school and specialty.
Enabling factors include the woman's resources necessary
to facilitate screening, for example, the level of insurance
coverage. Organizational factors include the health deliv-
ery system, office vs. hospital etc. Situational factors/cues
to trigger action for cervical cancer screening behavior per-
taining to the method of selection for a Pap test include
health status and the numbers of visits to physician. Pre-
vention behavior includes having a physician recommen-
dation for screening and prior utilization. Reinforcing
factors include geographic area because practice patterns,CytoJournal 2007, 4:16 http://www.cytojournal.com/content/4/1/16
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insurance and HMO penetration, can influence screening
and the method selected.
The advantages of Walsh and McPhee [34] model of
assessing choice are numerous and include a focus on
patient-physician interactions and their unique behavio-
ral factors. The model does not ignore the health care
delivery system; neither does it ignore the cost, efficacy
and efficiency of the Pap test as a screening tool. Finally,
the model approach for identification of barriers in a sys-
temic and systematic way making it easy to investigate.
Patient barriers
Many patient barriers to cervical screening in general have
been described previously [35] including ethnicity (e.g.
African -American), inability to speak/understand the
English language, no health insurance or being self
insured, an unfinished high school education, fatalistic
attitudes (including belief that cancer is bad luck, not
wanting to know if one has cancer), lack of family sup-
port, unable to drive, lower socio-economic status etc.,
including the inability to afford co-pays. However, a rela-
tionship of these factors to the use of conventional Pap
smears or LBC has not been explored.
Provider barriers
Controversial recommendations as discussed above
regarding the use of the different technology used for cer-
vical screening, inability to locate the medical records in
terms of deciding on a schedule for a regular follow up for
screening, the level of knowledge about different tech-
niques used for cervical screening, the education/speciali-
zation of a provider are the barriers which may impact
cervical screening.
System barriers
Sometimes the health care system is not well-organized so
that it can facilitate screening. Therefore, the educational
workshop which focuses on different technologies for cer-
vical screening including advantages and disadvantages
may help patients as well as providers in selecting the pre-
ferred method of choice.
The University of Alabama at Birmingham experience
The cytopathology laboratory at the University of Ala-
bama Medical Center is an American-Society-of-Cytopa-
thology designated Center of Excellence. Approximately
250 physicians from more than seven health organiza-
tions/settings submit approximately 20,000 Pap tests
A cause and effect (fish-bone) diagram representing Walsh-McPhee Systems Model for Preventive Care Figure 1
A cause and effect (fish-bone) diagram representing Walsh-McPhee Systems Model for Preventive Care.
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annually to this laboratory. These organizations included
University Hospital, physicians' offices, the Birmingham
Veterans Administration Medical Center, Children's Hos-
pital of Alabama, and a large outreach programs around
North Central Alabama, including the greater metropoli-
tan areas of Birmingham and Huntsville, Alabama.
The laboratory is manpowered by six cytopathologists
(with 8–28 year experience), five cytotechnologists (5–28
years experience), and three medical laboratory assistants
(with 2–5 years of experience). All cytologic and histo-
logic data is kept in the Cerner Laboratory Information
System®. This data is used for clinical, cytological and his-
tological correlation including quality control monitoring
which is a continuous process as required by various
accreditation agencies.
Since 1997 when UAB was selected as one of the four
national centers for the ALTS trial, the cytology laboratory
has utilized LBC. After the issuance of the new Bethesda
System and the new guidelines for management of cervi-
cal intraepithelial lesions in 2001, the laboratory wit-
nessed a gradual replacement of conventional Pap smear
with ThinPrep® LBC (Figure 2).
Currently, 99% of Pap tests are LBC and the remaining 1%
are conventional Pap tests. During conversion to Thin-
Prep®  we noticed a statistically significant increase in
unsatisfactory specimens and low grade squamous
intraepithelial lesions (LGSIL) (Chi-square for trend, P <
0.01). This was collaborated by significant decrease in
high grade squamous intraepithelial lesions (HGSIL) rates
(Chi Square for trends, P < 0.01). On the other hand, the
rate atypical squamous cells of undetermined significance
(ASCUS) remained the same (Figure 3).
The changes in these rates may be explained by the con-
version to LBC. However, we cannot exclude other rea-
sons such as a change in population demographic and/or
a learning-curve effect associated with the adoption of the
new Bethesda System or the new guidelines for manage-
ment of cervical intraepithelial lesions. In the study
period, we did not have a change in manpower in the lab-
oratory to explain these observed trends in diagnostic cat-
egories.
To investigate these observations further, we retrieved all
conventional Pap smear reports issued during the period
(04/05–04/06) and we determined who ordered the Pap
test and from where was it ordered (place of care: VA,
Children Hospital, Ob/Gyn service, Hem/Onc service, Pri-
mary Care, and others). Additionally, we compared the
diagnostic categories for conventional Pap tests to the
diagnostic category for LBC for each of these services. Last
year, we received 228 conventional Pap smear requests/
Decrease in the fraction of conventional Pap smear submit- ted to the Cytology Laboratory, University of Alabama Medi- cal Center, in the last Five years Figure 2
Decrease in the fraction of conventional Pap smear submit-
ted to the Cytology Laboratory, University of Alabama Medi-
cal Center, in the last Five years.
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orders compared to 20,163 LBC, showing that the practic-
ing pattern has been converted dramatically to the use of
LBC. Of these, 43 smears came from the VA, 67 smears
came from Radiation Oncologists, 27 from Rehabilitation
and Physical Medicine, and 13 from Children's Hospital.
Very few came from specialized services. The proportion
of Pap tests submitted as conventional tests has seen to be
inversely related to the total number of Pap test (Figure 4),
further suggesting that experience with the Pap test is
likely lead to adoption of new technology.
In conclusion, we suggest that the use of Walsh and
McPhee [34] Systems Model of Clinical Preventive Care to
determine patient and provider barriers for using LBC in
cervical screening [34] is useful. Although, socio-eco-
nomic barriers are explored in the literature in relation to
the cervical screening in general, the factors which may
affect for the patients as well as providers for the use of
recent techniques to obtain Pap test has not been
explored. Exploration of these factors, in turn, will help in
better deliverance of successful prevention program for
cervical screening.
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